Memantine XR
Phase 2Small molecule
Memantine XR is one of 116 small molecule programs targeting Cognitive impairment. It is currently in Phase 2.
3
Indications
3
Total Trials
1
Active Trials
115
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Activase
RochePreclinical
Folvite
Eli LillyPreclinical
Memantine XR
SSheppard Pratt Health System
Phase 2
Proamatine
TakedaPreclinical
Pradaxa
Boehringer IngelheimPreclinical
Haldol
DDePuy Orthopaedics
Preclinical
Zantac 150
CChattem
Preclinical
Direct Anticoagulant
BayerPreclinical
Botulinum Toxin a
GSKPreclinical
Anticoagulants
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Memantine XR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSheppard Pratt Health System